Summary
Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast Spray, a wound-healing agent; Ebrantil, an anti-dysuria agent; Ecclock gel for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc herniation; and Seprafilm, an adhesion barrier used primarily in surgery and gynecology to reduce complications from post-operative adhesions. It also provides agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone and Metamifop rice herbicides; Salinomycin, an anti-coccidial feed additive for chickens; and Uroston, urinary stone dissolution and elimination acceleration agent for cattle. In addition, the company is developing KMW-1 for the removal of eschar; KAR, which is in phase III clinical trial for the treatment of head lice; ART-001 that is in phase II clinical trial for the treatment of refractory vascular malformations; ART-648, which is in phase II clinical trial for the treatment of bullous pemphigoid; BBI-4000 that is in phase I clinical trial for primary palmoplantar hyperhidrosis; KP-483, which is in phase I clinical trial for the treatment of solid tumors; and NM26-2198 that is in phase I clinical trial for the treatment of atopic dermatitis. Further, it is involved in the rental of Bunkyo Green Court. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.
History
Kaken Pharmaceutical Co., Ltd. was established in 1951 in Tokyo, Japan, as a producer of dosage forms and pharmaceuticals such as tablets, capsules, and ointments. Since then, the company has expanded its presence in the global market, establishing subsidiaries in the U.S., France, and Germany and expanding operations in Asia and the Middle East.
Mission
Since its establishment, Kaken Pharmaceutical Co., Ltd. has been dedicated to designing and delivering innovative, safe and effective medications to patients, with a dedication to improving the quality of life for people around the world.
Vision
Kaken envisions a world where advances in the development of medicines, and access to life sustaining medications is available for all.
Key Team
Satoshi Murakami (Chief Officer of Regulatory Affairs Division)
Norihide Oizumi (Chief Officer of Production Division, Corp. Officer & GM of Shizuoka Factory)
Mr. Masanao Shimano Ph.D. (Corp. Officer)
Mr. Masashi Suzudo (GM of Corp. Planning & Coordination Department and Director)
Mr. Hironobu Ogura (Chief of Drug Research Centers)
Hirofumi Fujii (Corp. Officer)
Recognition and Awards
Kaken Pharmaceutical Co., Ltd. has been awarded numerous awards for its commitment to the research and development of innovative and effective treatments for the medical community. These awards include the Kaken Prize , the Kaken Industry Award , and the International Pharmaceutical Joint Venture Award .
References
